UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6×FEC versus 3×FEC/3×Docetaxel

BMC cancer, 2011-04, Vol.11 (1), p.140-140, Article 140

2011

Volltextzugriff (PDF)

Pretreatment quality of life, performance status and their relation to treatment discontinuation and treatment changes in high-risk breast cancer patients receiving chemotherapy: results from the prospective randomized ADEBAR trial

Breast cancer (Tokyo, Japan), 2017-03, Vol.24 (2), p.319-325

2017

Volltextzugriff (PDF)

Quadratic modules in R[[X]]

Proceedings of the American Mathematical Society, 2010-01, Vol.138 (1), p.75-84

2010

Volltextzugriff (PDF)

ABC3 Consensus: Assessment by a German Group of Experts

Breast care (Basel, Switzerland), 2016-01, Vol.11 (1), p.61-70

2016

Volltextzugriff (PDF)

Prospective multi-center study for quantification of chemotherapies and CTX-related direct medication costs avoided by use of biomarkers uPA and PAI-1 in primary breast cancer

Breast (Edinburgh), 2013-08, Vol.22 (4), p.436-443

2013

Volltextzugriff (PDF)

Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial

Breast cancer research and treatment, 2017-10, Vol.165 (3), p.573-583

2017

Volltextzugriff (PDF)

De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab P

Journal of clinical oncology, 2017-09, Vol.35 (26), p.3046-3054

2017

Volltextzugriff (PDF)

The Membership Problem for finitely generated quadratic modules in the univariate case

Journal of pure and applied algebra, 2012-10, Vol.216 (10), p.2204-2212, Article 2204

Augustin, Doris

2012

Volltextzugriff (PDF)

Differential impact of prognostic parameters in hormone receptor–positive lobular breast cancer

Cancer, 2020-11, Vol.126 (22), p.4847-4858

2020

Volltextzugriff (PDF)

De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 trial

The lancet oncology, 2022-05, Vol.23 (5), p.625-635

2022

Volltextzugriff (PDF)

4th International Consensus Conference on Advanced Breast Cancer (ABC4), Lisbon, November 4, 2017: ABC4 Consensus: Assessment by a Panel of German Experts

Geburtshilfe und Frauenheilkunde, 2018-05, Vol.78 (5), p.469-480

2018

Volltextzugriff (PDF)

ABC5 International Consensus Conference on Advanced Breast Cancer, Lisbon, 16 November 2019: Commentary by the German panel of experts on the ABC5 voting results

Geburtshilfe und Frauenheilkunde, 2020-06, Vol.80 (6), p.588-600

2020

Volltextzugriff (PDF)

Mammazentrum Ostbayern – Ein Kompentenzzentrum zur flächendeckenden optimalen Versorgung von Brustkrebspatientinnen

Breast care (Basel, Switzerland), 2006-08, Vol.1 (4), p.274-275

Augustin, Doris

2006

Volltextzugriff (PDF)

Verlässlich, menschlich, lebenserfahren

NeuroTransmitter, 2023-11, Vol.34 (11), p.18-18

2023

Volltextzugriff (PDF)

Abstract P4-10-05: Predictive value of HER2 expression, early response and tumor infiltrating lymphocytes (TILs) on efficacy of de-escalated pertuzumab+trastuzumab in the neoadjuvant WSG-ADAPT-HER2+/HR- trial

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P4-P4-10-05

2020

Volltextzugriff (PDF)

Abstract P4-17-06: Treatment strategies in male breast cancer: Results of a prospective multicenter study

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P4-P4-17-06

2020

Volltextzugriff (PDF)

A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study

Breast cancer research and treatment, 2017-01, Vol.161 (1), p.63-72

2017

Volltextzugriff (PDF)

4. Internationale Konsensuskonferenz zum fortgeschrittenen Mammakarzinom (ABC4), Lissabon, 04.11.2017: ABC4-Konsensus: Bewertung durch eine deutsche Expertengruppe

Senologie (Stuttgart), 2018-12, Vol.15 (4), p.238-249

2018

Volltextzugriff (PDF)

The Impact of Age on Quality of Life in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Comparative Analysis From the Prospective Multicenter Randomized ADEBAR trial

Clinical breast cancer, 2017-04, Vol.17 (2), p.100-106

2017

Volltextzugriff (PDF)

Correction to: Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial

Breast cancer research and treatment, 2019-05, Vol.175 (1), p.265-266

2019

Volltextzugriff (PDF)

Impact of PIK3CA mutation status on immune marker response and pCR in the WSG-ADAPT HER2+/HR+ phase II trial

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.572-572

2018

Volltextzugriff (PDF)

International Consensus Conference for Advanced Breast Cancer, Lisbon 2019: ABC5 Consensus – Assessment by a German Group of Experts

Breast care (Basel, Switzerland), 2020-02, Vol.15 (1), p.82-95

2020

Volltextzugriff (PDF)

1 – 25 von 78

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(70)
Mit Volltextzugriff
(73)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6×FEC versus 3×FEC/3×Docetaxel

Pretreatment quality of life, performance status and their relation to treatment discontinuation and treatment changes in high-risk breast cancer patients receiving chemotherapy: results from the prospective randomized ADEBAR trial

Quadratic modules in R[[X]]

ABC3 Consensus: Assessment by a German Group of Experts

Prospective multi-center study for quantification of chemotherapies and CTX-related direct medication costs avoided by use of biomarkers uPA and PAI-1 in primary breast cancer

Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial

The Membership Problem for finitely generated quadratic modules in the univariate case

Differential impact of prognostic parameters in hormone receptor–positive lobular breast cancer

De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 trial

Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR- Trial

4th International Consensus Conference on Advanced Breast Cancer (ABC4), Lisbon, November 4, 2017: ABC4 Consensus: Assessment by a Panel of German Experts

ABC5 International Consensus Conference on Advanced Breast Cancer, Lisbon, 16 November 2019: Commentary by the German panel of experts on the ABC5 voting results

Mammazentrum Ostbayern – Ein Kompentenzzentrum zur flächendeckenden optimalen Versorgung von Brustkrebspatientinnen

Verlässlich, menschlich, lebenserfahren

Abstract P4-10-05: Predictive value of HER2 expression, early response and tumor infiltrating lymphocytes (TILs) on efficacy of de-escalated pertuzumab+trastuzumab in the neoadjuvant WSG-ADAPT-HER2+/HR- trial

Abstract P4-17-06: Treatment strategies in male breast cancer: Results of a prospective multicenter study

A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study

4. Internationale Konsensuskonferenz zum fortgeschrittenen Mammakarzinom (ABC4), Lissabon, 04.11.2017: ABC4-Konsensus: Bewertung durch eine deutsche Expertengruppe

The Impact of Age on Quality of Life in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Comparative Analysis From the Prospective Multicenter Randomized ADEBAR trial

ABC5 – Internationale Konsensuskonferenz zum fortgeschrittenen Mammakarzinom, Lissabon, 16.11.2019 – Deutsche Expertengruppe kommentiert ABC5-Abstimmungsergebnisse

Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer

Correction to: Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial

Impact of PIK3CA mutation status on immune marker response and pCR in the WSG-ADAPT HER2+/HR+ phase II trial

International Consensus Conference for Advanced Breast Cancer, Lisbon 2019: ABC5 Consensus – Assessment by a German Group of Experts

Suchergebnisse filtern